Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

Short summary

In high-risk ambulatory cancer patients, daily rivaroxaban (10 mg) did not significantly lower the incidence of venous thromboembolism (VTE) or VTE-related death over 180 days compared to placebo (6.0% vs. 8.8%, P=0.10). However, during the intervention period, rivaroxaban showed a substantially lower incidence of these events (2.6% vs. 6.4%).

AI-generated from the title and abstract; the full text is not read.